**Product Name: Recombinant Human LILRB4 (C-Fc)**
**Catalog #: PHH2067**

## Summary

| | |
|---|---|
| **Name** | LILRB4/ILT3/CD85k |
| **Purity** | Greater than 95% as determined by reducing SDS-PAGE |
| **Endotoxin level** | <1 EU/μg as determined by LAL test. |
| **Construction** | Recombinant Human Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4 is produced by our Mammalian expression system and the target gene encoding Gln22-Glu259 is expressed with a human IgG1 Fc tag at the C-terminus. |
| **Accession #** | Q8NHJ6 |
| **Host** | Human Cells |
| **Species** | Human |
| **Predicted Molecular Mass** | 53.2 KDa |
| **Formulation** | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
| **Shipping** | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
| **Stability&Storage** | Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
| **Reconstitution** | Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |

## SDS-PAGE image



**Product Name: Recombinant Human LILRB4 (C-Fc)**
**Catalog #: PHH2067**

## Background

| | |
|---|---|
| **Alternative Names** | Leukocyte immunoglobulin-like receptor subfamily B member 4; Mast cell surface glycoprotein Gp49B; CD85k; Lilrb4; Gp49b |
| **Background** | Mouse Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4 (LILRB4/CD85k/ILT3) is an approximately transmembrane glycoprotein that negatively regulates immune cell activation. Mouse LILRB4 consists of a 215 amino acid (aa) extracellular domain with two Ig-like domains, a 22 aa transmembrane segment, and a 75 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM). Within the ECD, mouse LILRB4 shares 45% and 77% aa sequence identity with human and rat LILRB4, respectively. Alternative splicing of mouse LILRB4 generates a potentially soluble isoform that lacks the transmembrane segment. LILRB4 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC). Ligation of LILRB4 triggers ITIM-mediated inhibition of cellactivating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection. Soluble LILRB4 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL. In turn, CD8+ Ts cells induce LILRB4 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC. |

## Note

For Research Use Only , Not for Diagnostic Use.